HMGB1/GPC3 dual targeting vaccine induces dendritic cells-mediated CD8
cancer
immunology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
17 Mar 2023
17 Mar 2023
Historique:
received:
12
10
2022
revised:
15
12
2022
accepted:
01
02
2023
entrez:
7
3
2023
pubmed:
8
3
2023
medline:
8
3
2023
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is a fatal malignant tumor, but effective clinical interventions are limited. PLGA/PEI-mediated DNA vaccine encoding the dual targets of high-mobility group box 1 (HMGB1) or GPC3 was developed for HCC treatment. Compared with PLGA/PEI-GPC3 immunization, PLGA/PEI-HMGB1/GPC3 co-immunization significantly inhibited the subcutaneous tumor growth, while increasing the infiltration of CD8
Identifiants
pubmed: 36879804
doi: 10.1016/j.isci.2023.106143
pii: S2589-0042(23)00220-1
pmc: PMC9984564
doi:
Types de publication
Journal Article
Langues
eng
Pagination
106143Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Nat Rev Immunol. 2020 Jan;20(1):7-24
pubmed: 31467405
Oncol Rep. 2013 Jan;29(1):87-94
pubmed: 23042506
Mol Ther Oncolytics. 2021 Nov 29;24:1-13
pubmed: 34977338
Front Oncol. 2021 May 10;11:652768
pubmed: 34041022
J Control Release. 2019 Aug 28;308:14-28
pubmed: 31265882
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Cancer Res. 2005 Oct 1;65(19):9089-98
pubmed: 16204084
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33712445
Nat Rev Immunol. 2021 Nov;21(11):718-738
pubmed: 33981085
J Exp Clin Cancer Res. 2019 Apr 5;38(1):146
pubmed: 30953535
Clin Cancer Res. 2018 Jul 1;24(13):3014-3025
pubmed: 29545464
J Cell Physiol. 2021 May;236(5):3406-3419
pubmed: 33107103
J Control Release. 2013 Sep 28;170(3):452-9
pubmed: 23774102
Cancers (Basel). 2022 Sep 17;14(18):
pubmed: 36139670
J Gene Med. 2000 Mar-Apr;2(2):128-34
pubmed: 10809146
Gastroenterology. 2003 Jul;125(1):89-97
pubmed: 12851874
Hepatology. 2018 Aug;68(2):723-750
pubmed: 29624699
J Leukoc Biol. 2007 Jan;81(1):84-91
pubmed: 17035340
Colloids Surf B Biointerfaces. 2017 Nov 1;159:217-231
pubmed: 28797972
Cancer Immunol Res. 2018 Jul;6(7):835-847
pubmed: 29764836
J Biomed Nanotechnol. 2014 Sep;10(9):2332-49
pubmed: 25992460
Hum Vaccin Immunother. 2014;10(11):3153-64
pubmed: 25625927
Am J Cancer Res. 2020 Sep 01;10(9):2993-3036
pubmed: 33042631
Br J Cancer. 2021 Jan;124(2):359-367
pubmed: 32929195
J Hepatol. 2015 Jul;63(1):114-21
pubmed: 25681553
Toxicol Rep. 2019 Mar 02;6:253-261
pubmed: 30911468
Korean J Hepatol. 2009 Sep;15(3):391-423
pubmed: 19783891
J Exp Clin Cancer Res. 2015 May 20;34:51
pubmed: 25986235
EMBO Rep. 2004 Aug;5(8):825-30
pubmed: 15272298
Oncoimmunology. 2017 Jul 11;6(10):e1346764
pubmed: 29123959
Eur J Cancer. 2011 Feb;47(3):333-8
pubmed: 21112773
Clin Cancer Res. 2020 Oct 1;26(19):5162-5171
pubmed: 32513836
Biomaterials. 2011 May;32(14):3679-88
pubmed: 21333351
Int J Clin Exp Pathol. 2015 Jun 01;8(6):6262-8
pubmed: 26261503
Cancer Immunol Immunother. 2016 Jan;65(1):93-9
pubmed: 26093657
Immunotherapy. 2021 Apr;13(5):371-385
pubmed: 33525928
Immunol Rev. 2007 Dec;220:35-46
pubmed: 17979838
Liver Int. 2022 Aug;42(9):2042-2054
pubmed: 34894051
Clin Cancer Res. 2018 Mar 1;24(5):1190-1201
pubmed: 29269377
Chembiochem. 2021 Feb 2;22(3):523-531
pubmed: 32909670
Mol Cancer. 2019 Aug 23;18(1):128
pubmed: 31443694
Cancer Sci. 2003 Mar;94(3):259-62
pubmed: 12824919
Mol Cell Biochem. 2010 Apr;337(1-2):251-8
pubmed: 19876719
Nat Biotechnol. 2019 Oct;37(10):1174-1185
pubmed: 31570898